Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
EDQM
0
USP
0
JP
0
Others
0
Listed Dossiers
Regulatory FDF Prices
NA
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers


1. 1195768-06-9
2. Dabrafenib (mesylate)
3. Gsk 2118436b
4. Dabrafenib Mesilate
5. Dabrafenib Mesylate [usan]
6. Unii-b6dc89i63e
7. Gsk-2118436 Mesylate
8. Gsk-2118436b
9. Methane Sulfonate Salt
10. Gsk2118436b
11. Gsk2118436 Mesylate
12. B6dc89i63e
13. Chebi:75048
14. Gsk-2118436b Mesylate
15. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide Methanesulfonate
16. Gsk2118436b, Methane Sulfonate Salt
17. Gsk-2118436 Methanesulfonate Salt
18. Gsk-2118436b Methanesulfonate Salt
19. Gsk2118436 Mesylate;gsk 2118436b
20. Dabrafenib Mesilate (jan)
21. Dabrafenib Mesylate (gsk-2118436)
22. Dabrafenib Mesylate (usan)
23. Dabrafenib Mesilate [jan]
24. Taflinar
25. N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic Acid
26. Dabrafenib Methanesulfonate
27. Tafinlar (tn)
28. Gsk2118436 Methane Sulfonate Salt
29. Dabrafenib Monomesylate
30. Gsk 2118436 Mesylate
31. Schembl1127269
32. Chembl2105729
33. Dabrafenib Mesylate [mi]
34. Dtxsid70152500
35. Amy30045
36. Bcp04738
37. Ex-a1559
38. Dabrafenib Mesilate [who-dd]
39. Hy-14660a
40. Mfcd20922872
41. S5069
42. Akos025396661
43. Ccg-270246
44. Cs-1641
45. Dabrafenib Mesylate [orange Book]
46. Ac-31302
47. As-17010
48. Ft-0696677
49. D10104
50. A903491
51. Sr-01000941590
52. Sr-01000941590-1
53. Q27145089
54. Gsk2118436 Ms Salt, Dabrafenib Ms Salt, Gsk2118436a Ms Salt
55. Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)- 2-fluorophenyl)-2,6-difluoro-, Methanesulfonate (1:1)
56. Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, Methanesulfonate (1:1)
57. Dabrafenib Mesylaten-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide, Methanesulfonic Acid; Dabrafenib Mesylate
58. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl)-2,6- Difluorobenzenesulfonamide Monomethanesulfonate
59. N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate
60. N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate
1. 1195765-45-7
2. Dabrafenib
| Molecular Weight | 615.7 g/mol |
|---|---|
| Molecular Formula | C24H24F3N5O5S3 |
| Hydrogen Bond Donor Count | 3 |
| Hydrogen Bond Acceptor Count | 14 |
| Rotatable Bond Count | 6 |
| Exact Mass | 615.08916689 g/mol |
| Monoisotopic Mass | 615.08916689 g/mol |
| Topological Polar Surface Area | 210 Ų |
| Heavy Atom Count | 40 |
| Formal Charge | 0 |
| Complexity | 910 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 2 |
* Melanoma:
Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4. 4 and 5. 1).
* Adjuvant treatment of melanoma:
Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.
* Non-small cell lung cancer (NSCLC):
Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.
Treatment of melanoma, Treatment of solid malignant tumours (excluding melanoma)
L01EC02
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
NDC Package Code : 84644-063
Start Marketing Date : 2025-07-09
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43177
Submission : 2025-12-31
Status : Active
Type : II






FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43177
Submission : 2025-12-31
Status : Active
Type : II

USDMF
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 43256
Submission : 2026-01-22
Status : Active
Type : II

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
NDC Package Code : 84644-063
Start Marketing Date : 2025-07-09
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
NDC Package Code : 0078-1462
Start Marketing Date : 2016-04-12
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 50384-6600
Start Marketing Date : 2023-07-03
End Marketing Date : 2026-12-31
Dosage Form (Strength) : POWDER (10kg/10kg)
Marketing Category : BULK INGREDIENT

NDC Package Code : 81955-0029
Start Marketing Date : 2023-03-16
End Marketing Date : 2027-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT

Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]About the Company : Fermion, a wholly owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, is a fully integrated CDMO offering API and formulation services. Its API portfolio inc...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.
About the Company : Founded in 2003, Seqens has evolved into a global leader in pharmaceutical solutions and specialty ingredients. The company supports customers in the development, scale-up, and man...
Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.
About the Company : Egis is an EU-based, vertically integrated generic pharmaceutical company with over 110 years of experience across the entire value chain. Renowned for reliable supply, proprietary...
TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.
About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...
About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

About the Company : Aspen Bio is a multifaceted company that was established in 2014. Aspen Bio defines development and novelty as a challenge for competitive markets to provide improved health servic...

About the Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceutical ingredients an...

About the Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceutical ingredients an...

About the Company : Jinan Tantu Chemicals Co., Ltd. operates as a Contract Development and Manufacturing Organization (CDMO) that serves pharmaceutical companies worldwide. Our core services include c...

About the Company : Shenzhen HwaGen Pharmaceutical Co., Ltd. (HwaGen Pharma) was founded in December of 2015 under the leadership of a “National 1000 Talents Program” expert. By leveraging its cor...

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Reply
24 Dec 2024
Reply
05 Aug 2024
Reply
24 Jan 2020
Reply
08 Aug 2018

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
68
PharmaCompass offers a list of Dabrafenib Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Dabrafenib Mesylate manufacturer or Dabrafenib Mesylate supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dabrafenib Mesylate manufacturer or Dabrafenib Mesylate supplier.
A Dabrafenib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dabrafenib, including repackagers and relabelers. The FDA regulates Dabrafenib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dabrafenib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Dabrafenib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.
A Dabrafenib supplier is an individual or a company that provides Dabrafenib active pharmaceutical ingredient (API) or Dabrafenib finished formulations upon request. The Dabrafenib suppliers may include Dabrafenib API manufacturers, exporters, distributors and traders.
click here to find a list of Dabrafenib suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.
A Dabrafenib DMF (Drug Master File) is a document detailing the whole manufacturing process of Dabrafenib active pharmaceutical ingredient (API) in detail. Different forms of Dabrafenib DMFs exist exist since differing nations have different regulations, such as Dabrafenib USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Dabrafenib DMF submitted to regulatory agencies in the US is known as a USDMF. Dabrafenib USDMF includes data on Dabrafenib's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dabrafenib USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Dabrafenib suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dabrafenib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Dabrafenib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Dabrafenib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Dabrafenib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dabrafenib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Dabrafenib suppliers with NDC on PharmaCompass.
Dabrafenib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dabrafenib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Dabrafenib GMP manufacturer or Dabrafenib GMP API supplier for your needs.
A Dabrafenib CoA (Certificate of Analysis) is a formal document that attests to Dabrafenib's compliance with Dabrafenib specifications and serves as a tool for batch-level quality control.
Dabrafenib CoA mostly includes findings from lab analyses of a specific batch. For each Dabrafenib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dabrafenib may be tested according to a variety of international standards, such as European Pharmacopoeia (Dabrafenib EP), Dabrafenib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dabrafenib USP).